OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Revumenib: a new era in acute leukemia treatment	265
Tumor-resident microbes: the new kids on the microenvironment block	261
Platelets: tailoring metastasis treatment	238
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	236
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	209
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	206
Subscription & copyright page	205
Spliced to kill: RNA mis-splicing derived cancer neoantigens	190
FBXW10: a male-biased E3 ligase in liver cancer	190
Advancements in organoid models emulating metastatic niches	181
Engineering growth factor ligands and receptors for therapeutic innovation	180
Navigating life as an early career researcher	175
Leveraging circulating microbial DNA for early cancer detection	163
Onco-condensates: formation, multi-component organization, and biological functions	162
Subscription and copyright page	154
Advisory Board and Contents	154
Subscription & copyright page	142
Accessing the vasculature in cancer: revising an old hallmark	136
Engine shutdown: migrastatic strategies and prevention of metastases	133
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	121
Neural hijacking in cancer metabolism: from nutrients to organelles	113
Subscription & copyright page	112
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	103
FGFR rearrangements: oncogenic drivers and therapeutic targets	102
Oncogenic competence: balancing mutations, cellular state, and microenvironment	100

Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	99
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	98
GOT2 consider the tumor microenvironment	97
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	93
Recent developments in myeloid immune modulation in cancer therapy	92
Gut microbiota – a double-edged sword in cancer immunotherapy	86
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	81
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	80
From prediction to precision: how immunopeptidomics advances neoantigen discovery	80
Benefits and opportunities of the transgenic Oncopig cancer model	77
The evolving landscape of brain metastasis: volume II	74
Crosstalk of T cells within the ovarian cancer microenvironment	74
Diet, nutrient supply, and tumor immune responses	74
Cell death, therapeutics, and the immune response in cancer	72
Chromatin as an old and new anticancer target	71
Regulation of metastatic organotropism	68
Advisory Board and Contents	68
Subscription & copyright page	67
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	66
Organellar pH as an emerging vulnerability to exploit in cancer	64
Genetic immune escape in cancer: timing and implications for treatment	62
Toward mutational epidemiology: using mutational signatures of environmental exposures to assess cancer risk	62
Planning for cancer: building accessible and high-quality survivorship care for all	62
Palmitate paves the way to lung metastasis	62
The emerging field of oncolytic virus-based cancer immunotherapy	60
Insights on ErbB glycosylation – contributions to precision oncology	60
Scaling data toward pan-cancer foundation models	60
Clinical and translational relevance of intratumor heterogeneity	59
Inflammation: the incubator of the tumor microenvironment	58
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	58
Subscription & copyright page	56
Advancing cancer precision surgery with the tumor coagulome	54
Updating cancer research with patient-focused networks	54
Advisory Board and Contents	53
Advisory Board and Contents	53
Advisory Board and Contents	53
Advisory Board and Contents	52
Cuproptosis in cancer: from molecular mechanisms to therapeutic intervention	51
Prospects for understanding and exploiting the consequences of hyperactivation lethality	51
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	50
Circulating cell-free DNA-based multi-cancer early detection	49
B7-H3: a robust target for immunotherapy in prostate cancer	49
Stress granules and hormetic adaptation of cancer	49
RHOA takes the RHOad less traveled to cancer	49
Emerging mechanisms of telomerase reactivation in cancer	48
Advisory Board and Contents	46
Advisory Board and Contents	46
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	46
Advisory Board and Contents	46
Molecular and clinical insights into early-onset endometrial cancer	46

Targeting TIM-3 to halt lung precancer progression	45
Subscription & copyright page	44
Beyond safety: suicide systems in cell-based cancer therapies	44
Advisory Board and Contents	43
Leveraging space innovations for cancer breakthroughs on Earth	43
A macrophage-neutrophil program drives mammary carcinogenesis	43
Time-of-day dependency of adoptive cell therapies	42
Neoantigen-directed therapeutics in the clinic: where are we?	42
RNA vaccines for cancer: revolutionizing immunization strategies	42
Subscription & copyright page	42
Orchestrating tumor-immune epigenetics via SERT–H3Q5ser axis	42
Branched chain amino acids and their aberrant metabolism in cancer	42
Mechanistic cancer prevention comes of age	41
The promise of TIL therapy for glioblastoma	41
Functional heterogeneity of fibroblasts in primary tumors and metastases	40
CAR T cell persistence in cancer	39
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	39
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	39
Advisory Board and Contents	38
Subscription & copyright page	38
Ferroptosis vulnerability in FLT3-mutant leukemia	37
ApCAFs: spatial niches and therapeutic insights across cancers	35
Advisory Board and Contents	35
Advisory Board and Contents	35
Neural circuits in lung adenocarcinoma modulate immunosurveillance	34
Engineered bacterial therapeutics for detecting and treating CRC	34
Advisory Board and Contents	34
Space in cancer biology: its role and implications	33
Dissecting histological transformation	33
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	33
Dying to survive: harnessing inflammatory cell death for better immunotherapy	32
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	31
Addressing the genetic/nongenetic duality in cancer with systems biology	31
Clonal evolution and hierarchy in myeloid malignancies	31
Advisory Board and Contents	31
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	31
Subscription & copyright page	31
Lifileucel: the first cellular therapy approved for solid tumours	30
NETscape or NEThance: tailoring anti-cancer therapy	30
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	30
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	30
Next-generation cancer vaccines and emerging immunotherapy combinations	30
Immunomodulation by endothelial cells: prospects for cancer therapy	30
Subscription & copyright page	29
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics	29
Genitourinary cancer neoadjuvant therapies: current and future approaches	29
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	28
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	27
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	26
Mesothelioma: a systemic therapy clinical trials snapshot	26
Subscription & copyright page	26
How cancer cells make and respond to interferon-I	25
Subscription & copyright page	25
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	25
Embracing diversity: macrophage complexity in cancer	25
Successfully targeting the cancer system with metronomics for medulloblastoma	25
Persisting cancer cells are different from bacterial persisters	24
Future perspectives on engineered T cells for cancer	24
Tissue architecture in tumor initiation and progression	24
Deciphering the roles of ABCB5 in normal and cancer cells	24
The extracellular matrix in cancer: from understanding to targeting	24
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	23
Subscription & copyright page	23
Think zebras: challenges and opportunities for treating rare cancers	23
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	23
TET2, tumor control, and CAR T cell hyperproliferation	22
Enhancing dendritic cells by inhibiting BCL2	22